Ardelyx Inc - Asset Resilience Ratio
Ardelyx Inc (ARDX) has an Asset Resilience Ratio of 32.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ARDX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Ardelyx Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Ardelyx Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down Ardelyx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ARDX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $184.64 Million | 32.06% |
| Total Liquid Assets | $184.64 Million | 32.06% |
Asset Resilience Insights
- Very High Liquidity: Ardelyx Inc maintains exceptional liquid asset reserves at 32.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ardelyx Inc Industry Peers by Asset Resilience Ratio
Compare Ardelyx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Ardelyx Inc (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Ardelyx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.21% | $196.69 Million | $501.60 Million | -3.28pp |
| 2024-12-31 | 42.49% | $185.17 Million | $435.75 Million | -12.22pp |
| 2023-12-31 | 54.72% | $162.83 Million | $297.58 Million | +40.11pp |
| 2022-12-31 | 14.61% | $27.77 Million | $190.07 Million | -14.91pp |
| 2021-12-31 | 29.52% | $44.26 Million | $149.91 Million | -17.83pp |
| 2020-12-31 | 47.36% | $95.45 Million | $201.56 Million | +21.80pp |
| 2019-12-31 | 25.55% | $66.38 Million | $259.78 Million | -23.17pp |
| 2018-12-31 | 48.72% | $89.32 Million | $183.33 Million | +11.61pp |
| 2017-12-31 | 37.11% | $58.59 Million | $157.90 Million | -22.12pp |
| 2016-12-31 | 59.22% | $126.22 Million | $213.13 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $116.95 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $113.41 Million | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more